UroGen Pharma, Q3 2026 Earnings Call Transcript

UroGen’s Zosturi launch continued to gain momentum, with third-quarter revenue up 35% sequentially to $68 million. New and repeat prescribing increased, and adoption is expanding in community practices. The company expects further sequential revenue growth in Q4 despite a typical holiday slowdown; it sees room to deepen use and broaden prescriber adoption, with direct-to-patient efforts planned around mid-2027. Management expects to reach profitability and generate positive cash flow in Q4 2026 using existing resources.

Jelmyto revenue was $21 million, pressured by a one-time reimbursement adjustment and competition from clinical trials; full-year revenue guidance is about $90 million. The FDA accepted UGN-103 for review with a June 14, 2027 decision target, and UroGen plans a 2028 launch if approved and assigned a permanent J code. Development also includes a planned Phase 3 trial in high-grade bladder cancer and continued UGN-104 enrollment. The company ended the quarter with $90.5 million in cash, equivalents and marketable securities.